Effect of hormone replacement therapies and selective estrogen receptor modulators in postmenopausal women with uterine leiomyomas: A literature review

Climacteric

Volumn 4, Issue 4, 2001, Pages 284-292

  Ang, W C ^a   Farrell, E ^a   Vollenhoven, B ^b  

^a MONASH MEDICAL CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Hormone replacement therapy; Leiomyoma; Postmenopausal; Selective estrogen receptor modulators; Tibolone

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TIBOLONE;

DRUG EFFECT; DRUG SAFETY; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT INDICATION; TUMOR GROWTH; UTERUS MYOMA;

EID: 0035665775     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/cmt.4.4.284.292     Document Type: Review

References (39)

1. Progestin and antiprogestin interactions with progesterone receptors in human myomas
2. Estrogen and progestin receptor levels in uterine leiomyoma: Relation to tumour histology and the phase of menstrual cycle
3. Comparison of cellular levels of steroid receptors in uterine leiomyoma and myometrium
4. Cytoplasmic progestin receptors in myomal and myometrial tissues. Concentrations and hormonal dependency
5. Fibroid growth in response to high-dose progestogen
6. Progesterone: A criticai role in the pathogenesis of uterine myomas
7. Delta 4-3-ketosteroid 5-alpha-oxidoreductase in human uterine leiomyoma
8. Steroidal treatment of myomas: Preoperative and long-term medical therapy
9. Bleeding patterns in recent postmenopausal outpatients with uterine myomas: Comparison between two regimens of HRT
10. A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas
11. Effect of tibolone on postmenopausal women with myomas
12. The effects of menopausal replacement therapy in women with uterine myomas
13. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women
14. Effects of post-menopausal hormone replacement on uterine leiomyoma growth measured by ultrasound
15. Effects of hormone replacement therapy on postmenopausal uterine myoma
16. Effects of hormone substitution in depot form on the uterus in a group of 50 perimenopausal women - A vaginosonographic study
17. Does the use of postmenopausal hormone replacement therapy influence the size of uterine leiomyomata? A preliminary report
18. Uterine findings by transvaginal sonography during percutaneous estrogen treatment in postmenopausal women
19. Uterine leiomyomata: Etiology, symptomatology, and management
20. Retroperitoneal leiomyoma presenting after hormone replacement therapy
21. Contraception, hormone replacement therapy and myomas
22. Growth of leiomyomata with estrogen-progestogen therapy
23. Steroidal treatment of myomas: Preoperative and long-term medical therapy
24. Use of transvaginal ultrasonography to monitor the effects of tamoxifen on uterine leiomyoma size and ovarian cyst formation
25. Paradoxical effects of tamoxifen on the woman's uterus. Apropos of 7 cases of myoma that appeared while under anti-estrogen treatment
26. Rapid growth of leiomyoma in patient receiving tamoxifen
27. Rapid enlargement of a uterine fibroid after clomiphene therapy
28. Effect of raloxifene on the endometrium: Will this be the ultimate key to its utilization?
29. Tamoxifen-induced growth of leiomyomas. A case report
30. Endometrial polyps, cystic glandular hyperplasia and atypical leiomyoma associated with tamoxifen therapy
31. Leiomyomas in patients receiving tamoxifen
32. Uterine leiomyosarcoma in a postmenopausal woman treated with tamoxifen: Case report
33. Uterine leiomyomata and endometrial proliferation in postmenopausal women treated with the anti-oestrogen tamoxifen
34. Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators
35. Effects of raloxifene in a guinea pig model for leiomyomas
36. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma